Colossal Biosciences Unveils AI Platform GenoMorph to Accelerate Dodo De-Extinction Efforts

Colossal Biosciences has officially launched GenoMorph, a sophisticated artificial intelligence platform designed to overcome the significant genetic data limitations inherent in de-extinction projects. By integrating advanced 3D morphology, comparative genomics, and developmental biology, the platform aims to identify critical genetic markers necessary to reconstruct extinct species. The technology is currently being deployed to address the dodo bird project, where researchers face the challenge of working with extremely limited genomic data compared to more robust samples available for other species like the woolly mammoth.

CEO and co-founder Ben Lamm describes GenoMorph as a "treasure map" for the dodo genome, capable of filtering through vast amounts of biological data to pinpoint specific genetic switches. The AI was trained on developmental data from over 70 bird species, including chickens and pigeons, to predict how DNA regions influence physical traits. To date, the team has identified approximately 2,300 promising DNA editing targets. Lamm emphasized the precision of this approach, stating, "The more precisely we can identify and validate these changes, the more informed our decisions become throughout the process."

Beyond the AI platform, Colossal is advancing its laboratory capabilities by utilizing lipid nanoparticles to deliver gene-editing tools directly into developing bird embryos. This method allows scientists to observe the impact of genetic modifications without waiting for full breeding cycles. Furthermore, the company has successfully cultivated essential germ cells from the Nicobar pigeon, the dodo’s closest living relative, marking a pivotal step in their strategy to eventually produce birds that carry dodo-specific traits.

The development of GenoMorph has garnered significant industry attention, underscored by the launch of NeoGenesis Capital by XPRIZE founder Peter Diamandis, which aims to support companies utilizing Colossal’s programmable biology platform. As these technologies converge, Colossal intends to apply these methodologies across diverse fields, including health and agriculture. While the company remains focused on the scientific rigor of its de-extinction efforts, the integration of AI represents a major shift toward making genetic engineering more controlled, precise, and testable for future conservation applications.